Skip to main content

Table 2 Summary of on-treatment COPD exacerbations (ITT population)

From: Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study

 

F/UMEC/VI 100/62.5/25 μg

FF/VI 100/25 μg + UMEC 62.5 μg

(N = 527)

(N = 528)

Patients with a mild, moderate or severe exacerbation, n (%)

134 (25)

145 (27)

 Mild

8 (2)

5 (< 1)

 Moderate

111 (21)

118 (22)

 Severe

22 (4)

31 (6)

 Moderate/Severe

129 (24)

142 (27)

Number of moderate/severe exacerbations, n (%)

 0

398 (76)

386 (73)

 1

105 (20)

111 (21)

  ≥ 2

24 (5)

31 (6)

  1. COPD chronic obstructive pulmonary disease, FF fluticasone furoate, ITT intent-to-treat, SD standard deviation, UMEC umeclidinium, VI vilanterol